Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test

If approved, the test could streamline the journey to diagnosis for more patients

- PMLiVE

Inizio appoints Stefanie Christmas as global head of DE&I

Christmas joins from Vynamic, where she founded the firm’s DE&I efforts in 2016

- PMLiVE

Rare diseases: not so rare after all

The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment

- PMLiVE

Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis

Atopic dermatitis affects over 26 million people in the US alone

- PMLiVE

Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis

Plaque psoriasis accounts for around 80-90% of the 125 million psoriasis cases worldwide

- PMLiVE

UCB’s bimekizumab shows continued improvement in hidradenitis suppurativa patients

There is currently only one approved biologic treatment for the inflammatory skin disease

- PMLiVE

The Considered appoints Bam Zahraie as chief experience officer

Zahraie was previously global innovation lead and associate managing director at Havas Health & You

- PMLiVE

The impact of pharma congresses on HCPs – virtual and in person

By Kieran Martinez

- PMLiVE

Webcast: Evolving Patient Journeys – How to generate deeper insights in a changing healthcare landscape

Watch part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years.

Inizio

Creating content for healthcare professionals

How to create content for health professionals

Catching the attention of time-strapped healthcare professionals is hard, but not impossible.

Springer Nature

- PMLiVE

Sanofi to cut US insulin prices by up to 78% in January 2024

The announcement follows similar moves by Novo Nordisk and Eli Lilly earlier this month

- PMLiVE

Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study

The treatment is already approved in the US for three disease states of prostate cancer

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links